{"id":29195,"date":"2023-02-09T03:20:12","date_gmt":"2023-02-09T03:20:12","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=29195"},"modified":"2023-05-01T15:25:19","modified_gmt":"2023-05-01T05:25:19","slug":"prescient-therapeutics-shareholder-replay-9th-february-2023","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/","title":{"rendered":"Prescient Therapeutics Shareholder Replay 9th February 2023"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gm8c4a277 gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gm3f9b549\" class=\"wp-block-gutentor-m4 section-gm3f9b549 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm2e5509\" class=\"wp-block-gutentor-m4-col col-gm2e5509 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm2e5509\" class=\"section-gm2e5509 gutentor-col-wrap\">\n<h2 class=\"has-text-align-center has-white-color has-text-color wp-block-heading\" style=\"font-size:33px\">Prescient Therapeutics Shareholder Briefing<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm03087c6\" class=\"wp-block-gutentor-m4 section-gm03087c6 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmf88597\" class=\"wp-block-gutentor-m4-col col-gmf88597 gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gmf88597\" class=\"section-gmf88597 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\" alt=\"\" class=\"wp-image-29204\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/797234416?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/reachmarkets.com.au\/wp-content\/uploads\/2019\/12\/play-icon-white.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm739940\" class=\"wp-block-gutentor-m4-col col-gm739940 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm739940\" class=\"section-gm739940 gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\"><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke  discussed:<\/p>\n\n\n\n<ul class=\"white wp-block-list\"><li>Prescient\u2019s diversified portfolio of both later stage and emerging assets for cancer treatment<\/li><li>Our lead targeted therapy, PTX-100, which is exhibiting promising data in a disease of unmet need<\/li><li>The potential significance of accelerating clinical development of PTX-100 in an orphan disease<\/li><li>How our OmniCAR and CellPryme cell therapy platforms allow us to partner with any CAR-T developer, giving us a \u2018shovels to the gold rush\u2019 position<\/li><\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 9 February 2023 at 11:00am (AEDT)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gm09e6430 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"speak has-text-color wp-block-heading\" style=\"color:#ffcc00\">Featured Speakers<\/h4>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\"><\/h3>\n\n\n\n<section id=\"gmc9019a7\" class=\"wp-block-gutentor-m4 section-gmc9019a7 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmbef44b\" class=\"wp-block-gutentor-m4-col col-gmbef44b gutentor-single-column  grid-lg-4 grid-md-12 grid-12\"><div id=\"section-gmbef44b\" class=\"section-gmbef44b gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gm6349a0\" class=\"wp-block-gutentor-m4-col col-gm6349a0 gutentor-single-column  grid-lg-4 grid-md-12 grid-12\"><div id=\"section-gm6349a0\" class=\"section-gm6349a0 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg\" alt=\"\" class=\"wp-image-27331\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped-150x150.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Steven Yatomi-Clarke<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">CEO and Managing Director<\/h4>\n\n\n\n<div style=\"height:0px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm3cbf50\" class=\"wp-block-gutentor-m4-col col-gm3cbf50 gutentor-single-column  grid-lg-4 grid-md-12 grid-12\"><div id=\"section-gm3cbf50\" class=\"section-gm3cbf50 gutentor-col-wrap\">\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":38,"featured_media":29204,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-29195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics Shareholder Replay 9th February 2023 - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics Shareholder Replay 9th February 2023 - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T03:20:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-01T05:25:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Adrian Montesano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adrian Montesano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/\"},\"author\":{\"name\":\"Adrian Montesano\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"headline\":\"Prescient Therapeutics Shareholder Replay 9th February 2023\",\"datePublished\":\"2023-02-09T03:20:12+00:00\",\"dateModified\":\"2023-05-01T05:25:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/\"},\"wordCount\":171,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/\",\"name\":\"Prescient Therapeutics Shareholder Replay 9th February 2023 - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\",\"datePublished\":\"2023-02-09T03:20:12+00:00\",\"dateModified\":\"2023-05-01T05:25:19+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics Shareholder Replay 9th February 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\",\"name\":\"Adrian Montesano\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"caption\":\"Adrian Montesano\"},\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics Shareholder Replay 9th February 2023 - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics Shareholder Replay 9th February 2023 - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/","og_site_name":"PTX Therapeutics","article_published_time":"2023-02-09T03:20:12+00:00","article_modified_time":"2023-05-01T05:25:19+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","type":"image\/png"}],"author":"Adrian Montesano","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Adrian Montesano","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/"},"author":{"name":"Adrian Montesano","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"headline":"Prescient Therapeutics Shareholder Replay 9th February 2023","datePublished":"2023-02-09T03:20:12+00:00","dateModified":"2023-05-01T05:25:19+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/"},"wordCount":171,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/","name":"Prescient Therapeutics Shareholder Replay 9th February 2023 - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","datePublished":"2023-02-09T03:20:12+00:00","dateModified":"2023-05-01T05:25:19+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-9th-february-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics Shareholder Replay 9th February 2023"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6","name":"Adrian Montesano","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","caption":"Adrian Montesano"},"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/29195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=29195"}],"version-history":[{"count":18,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/29195\/revisions"}],"predecessor-version":[{"id":29440,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/29195\/revisions\/29440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/29204"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=29195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=29195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=29195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}